An observational study in Fistula-in-ano, sponsored by Signum Surgical USA Inc.. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Signum Surgical USA Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Rectal Fistula with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Rectal Fistula · United States.
Among the 20 studies in Rectal Fistula with a site in United States, this one is one of 3 that started in 2025, is one of 5 observational ones, and was the 18th registered.
170 studies on the registry are indexed under Rectal Fistula; 45 are open to participants now.
Browse Rectal Fistula studies →7 of the 20 studies in Rectal Fistula with a site in United States are open now. Recruiting first, the newest first:
ECM Therapeutics, Inc. · Sites in United States
Ages 18+
RedDress Ltd. · Sites in United States, Israel
Ages 18+
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+
Aroa Biosurgery Limited · Sites in United States
Ages 18+
Sanford Health · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Rectal Fistula studies recruiting now, 18 (69%) set no upper age limit and 7 (27%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 85 across 46 observational studies indexed under Rectal Fistula.
Median enrollment 21 across the 15 interventional studies, 79 across the 5 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Signum Surgical USA Inc. as lead sponsor.
Signum Surgical USA Inc. has 1 study filed under Rectal Fistula — fewer than ten, so there is no comparison to draw.
3 of the studies in Rectal Fistula with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04190862Weill Medical College of Cornell UniversityE-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas | 2026-12-30 |
| NCT07021742Signum Surgical USA Inc.BioHealx® Anal Fistula Device Post Market Surveillance Study | 2027-02 |
| NCT07035925ECM Therapeutics, Inc.Study Evaluating the Safety and Efficacy of an ECM Hydrogel for the Treatment of Anorectal Fistulas | 2027-02-24 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Rectal Fistula with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This post market surveillance study is a single arm multicenter study to demonstrate the long-term durability and effectiveness of the BioHealx Anal Fistula Device for fistula-in-ano closure (internal and external fistula openings).
Patients presenting for treatment of mature, cryptogenic, transsphincteric, non-branching fistulas in ano via tissue apposition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will have their anal fistula treated with the BioHealx Anal Fistula Device.
Device: BioHealx
Subjects will have their anal fistula treated with the BioHealx Anal Fistula Device, a bioabsorbable implant designed to securely close the fistula internal opening, preventing reinfection, while allowing for drainage through the external opening during healing.
Successful Closure Repair
Successful closure repair of the anal fistula as determined by complete healing, i.e., internal and external opening closed (no evidence of an external opening present) without drainage
Time frame: 12 Months
Non-Recurrence Incidence
Non-recurrence incidence determined by continued closure of the external fistula opening.
Time frame: 24 and 36 Months
Fecal Incontinence Quality of Life
Fecal incontinence Quality of Life (FIQL) score at each follow-up visit (baseline visit and from 6-month and at subsequent follow-up visit) The FIQL score includes 29 items which form four scales: lifestyle, coping/behavior, depression/self-perception, and embarrassment. The FIQL scale range includes a range of response options across its items, from 1 to 4 for most items, 1 to 5 for one item, and 1 to 6 for another. Lower scores indicate lower quality of life.
Time frame: 6 Months, 9 Months, 12 Months, 24 Months, 36 Months
Fecal Incontinence Severity Index (FISI)
Fecal Incontinence Severity Index (FISI) at each follow-up visit (baseline visit and from 6-month and at each subsequent follow-up visit). The Fecal Incontinence Severity Index (FISI) Scale typically ranges from 0 to a maximum value 61. Higher scores on the FISI scale indicate a worse outcome, reflecting greater severity of fecal incontinence symptoms.
Time frame: 6 Month, 9 Month, 12 Month, 24 Month, 36 Month
Health Related Quality of Life
SF-36 Quality of life data will be collected (baseline visit and from 6-month and at each subsequent follow-up visit). Short Form 36 (SF-36) is a generic self-reported outcome measure that quantifies the quality of life in relation to health status. It is a 36-item valid and reliable evaluation with eight areas covering physical functioning, role limitations brought on by physical issues, bodily pain, general health perceptions, vitality, social functioning, role limitations brought on by emotional issues, and perceived mental health. The SF-36 also contains a single question called "health transition" that measures how respondents feel their over health status has changed over the course of a year. The scores range from 0-100 (the worst possible to the most possible)
Time frame: 6 Months, 9 Months, 12 Months, 24 Months, 36 Months
Pain Score
Wong-Baker FACES Pain scores will be recorded at each follow-up visit (baseline visit and from 6-month and at each subsequent follow-up visit). The FACES Pain Scale ranges from 0 (no pain) to 10 (the worst pain).
Time frame: 6 Months, 9 Months, 12 Months, 24 Months, 36 Months
Rescue Analgesic and Therapeutic Antibiotic Use
Occurrence of use of rescue analgesic and/or therapeutic antibiotics beyond post-operative Day 5 after the surgery and at each follow-up visit.
Time frame: 6 Weeks, 3 Months, 6 Months, 9 Months, 12 Months, 24 Months, 36 Months
Device and Procedure Related Adverse Events
Measurement of device and/or procedure related adverse events will be recorded.
Time frame: 6 Weeks, 3 Months, 6 Months, 9 Months, 12 Months, 24 Months, 36 Months
Adverse Event Comparison
Measurement of, incidence, severity and persistence of device and/or procedure related adverse events will be recorded and compared with previous BioHealx Anal Fistula Device clinical results and relevant comparator devices (e.g. cutting seton) and procedures (e.g., LIFT).
Time frame: 6 Weeks, 3 Months, 6 Months, 9 Months, 12 Months, 24 Months, 36 Months
Occurrence of Fecal Incontinence
Fecal continence will be measured through combination of the patient reported Fecal Incontinence Quality of Life questionnaire (FIQL) and the Fecal Incontinence Severity Index questionnaire (FISI) scores at baseline and subsequent periods. Fecal incontinence Quality of Life (FIQL) score at each follow-up visit (baseline visit and from 6-month and at subsequent follow-up visit) The FIQL score includes 29 items which form four scales: lifestyle, coping/behavior, depression/self-perception, and embarrassment. The FIQL scale range includes a range of response options across its items, from 1 to 4 for most items, 1 to 5 for one item, and 1 to 6 for another. Lower scores indicate lower quality of life. The Fecal Incontinence Severity Index (FISI) Scale typically ranges from 0 to a maximum value 61. Higher scores on the FISI scale indicate a worse outcome, reflecting greater severity of fecal incontinence symptoms.
Time frame: Baseline, 6 Weeks, 3 Months, 6 Months, 9 Months, 12 Months, 24 Months, 36 Months
Rescue Analgesic and Therapeutic Antibiotic Comparison
Rescue analgesic and therapeutic antibiotic use will be recorded and compared with previous BioHealx Anal Fistula Device clinical results and other relevant fistula treatments.
Time frame: 6 Weeks, 3 Months, 6 Months, 9 Months, 12 Months, 24 Months, 36 Months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Feb 2027, 20 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Oct 2026 → Feb 2027 and completion Dec 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.